Major investment by Central Manchester University Hospitals NHS Trust is set to bring benefits to more than a million patients it treats every year.
A new £95 million investment in laboratory testing and diagnostic services at Central Manchester University Hospitals NHS Foundation Trust (CMFT) over a 10-year term will have a major impact on the wide range of general and specialist services provided to CMFT patients who come from all over the Greater Manchester region and beyond.
To maximise the quality and efficiency of its pathology services and harness developments in analytical technology, CMFT has awarded a pathology contract to Roche Diagnostics following a thorough competitive tender process.
Immediate benefits will be realised
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.